CPhI Milan 2024

This year CPHI Worldwide will be at the Fiera Milano from 8 to 10 October and Chemelectiva S.r.l. is pleased to announce that it will be attending with its own booth 3F58. Contact us to schedule your meeting or come by our booth. We hope to see you there. We would also like to take...

CPhI Japan 2024

Chemelectiva will participate in CpHI Japan 2024. CPhI Japan will be held from 17 to 19 April at Tokyo Big Sight Japan. CPhI Japan is Japan’s largest and most comprehensive pharmaceutical event; represents an important opportunity to come into contact with a large number of exhibitors operating in the various pharmaceutical fields and participate in...

DCAT NY 2024

DCAT NY 2024

February 12, 20240

Also this year our CEO, Graziano Castaldi, will be at DCAT Week in New York. DCAT Week is the premier event held annually in New York City for companies engaged in the Global Bio/Pharmaceutical Manufacturing Value Chain. It is hosted by the Drug, Chemical & Associated Technologies Association (DCAT), a not-for-profit, member-supported, global business development...

Happy New Year From Chemelectiva

CHEMELECTIVA’s Team wishes you all the best for a happy Holiday Season and a Happy New Year! 2024 promises to be a year full of commitments and news for Chemelectiva. As previously announced, with the new year, the works started in March 2023 for the construction of the new cGMP manufacturing plant will be completed....

ChemOutsourcing

ChemOutsourcing

October 4, 20230

In the current month, our CEO Graziano Castaldi attended ChemOutsourcing, the largest trade show dedicated to APIs and Pharmaceutical Ingredients based in the United States. The sixteenth edition, which took place September 6-8, 2023 at the Parsippany Hilton in Parsippany, NJ, was again attended this year by many representatives of the chemical and pharmaceutical industry,...

Clascoterone

Clascoterone

October 4, 20230

Clascoterone is an androgen receptor inhibitor developed as a cream and solution for the treatment of androgen-dependent skin disorders, including androgenetic alopecia and acne vulgaris. In August 2020, 1% clascoterone cream received its first approval in the United States for the topical treatment of acne vulgaris in patients 12 years of age and older. Clinical...

Ruxolitinib

Ruxolitinib

October 4, 20230

Ruxolitinib, a Janus kinase inhibitor with selectivity for the JAK1 and JAK2 subtypes of this enzyme, was approved in 2011 by the FDA for the treatment of patients with myelofibrosis and polycythemia vera, has now also received marketing authorization from the European Commission for the treatment of nonsegmental vitiligo. Chemelectiva has developed a new efficient...

CpHI Barcelona 2023

Chemelectiva S.r.l. will participate in CpHI Barcelona 2023. CPhI Worldwide – Chemical Pharmaceutical Ingredients is the International Exhibition dedicated to the pharmaceutical industry, a reference point for industry professionals from all over the world. CPhI Worldwide 2023 will be held at the Barcelona trade show from October 24 to 26. Contact us to schedule a...